113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)

Catalog:CDCLP24-013-L

Unit Size:

5 mL

Specifications QA & Reviews

Description

The formulation is from the literature DOI: 10.1073/pnas.2207841119. The special lipids synthesised enable specific targeting of lymph nodes, and the formulation can be used to develop mRNA cancer-targeted vaccines without the need to modify any of the active targeting ligands. Compared with LNPs formulated with ALC-0315, a key component in the US Food and Drug Administration (FDA)-approved Comirnaty, 113-O12B showed significantly reduced mRNA expression in the liver and higher expression in LNs after subcutaneous (SC) injection.

Lipid composition

113-O12B/Chol/DOPE/DMG-PEG (16:4.8:3:2.4, mole ratio)

Related Products

Product Name	Catalog	Lipid composition	Price
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-007-L	DLin-MC3-DMA/β-sitosterol/DMG-PEG2K/DSPC (50:36.5:3.5:10, mole ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-009-L	DPPC:MSPC:DSPE-PEG2000 (86.5:9.7:3.8, mol %)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-011-L	AA3-DLin/DOPE/Cholesterol/DMG-PEG (40:40:25:0.5, molar ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-004-L	DB-lipidoids(11-10-8)/DOPE/Cholesterol/DMG-PEG (40:10:48.8:1.5, mole ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-006-L	C12-494/DOPE/Chol/Lipid-PEG2K (51.4:14:32.7:1.9, mole ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-003-L	SM-102/DSPC/cholesterol/FPD (50:10:38.5:1.5, mole ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-001-L	DOTAP/Cholesterol/DSPC/DSPE-PEG2000 (50:38.5:10:1.5, mole ratio)	INQUIRY
113-O12B-Lipid Nanoparticles (Targeted to Lymph Nodes)	CDCLP24-010-L	DPPC:MSPC:DSPE-PEG2000 (21.6:2.6:1.0, mole ratio)	INQUIRY

Products

Fill out the form below
to receive a quote

GET A QUOTE